Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported an option exercise and related stock sale. She exercised options to acquire 152,068 shares of common stock at $9.0600 per share and sold 177,068 shares in open-market transactions at a weighted-average price of $20.8281 per share under a Rule 10b5-1 trading plan adopted on 3/13/26, with individual sale prices ranging from $20.29 to $21.14. The exercised options, granted on 03/08/2022, vested 25% on each of the first four anniversaries of the grant date.
A Form 144 notice for ALHC covers a proposed sale of up to 177,068 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $3,753,841.60 and 206,733,823 shares outstanding. The shares include stock acquired via Exercise of Stock Options and RSU/PSU awards. It also lists prior 10b5-1 sales of 30,000 shares on May 15, 2026, for $482,567.00 and 30,000 shares on June 15, 2026, for $586,424.50.
Alignment Healthcare, Inc. CEO and director John E. Kao reported open-market sales of 298,000 shares of common stock on July 10, 2026. The shares were sold in multiple transactions at weighted-average prices of $19.8122 and $20.6471 per share under a Rule 10b5-1 trading plan adopted on November 21, 2025, and include sales from a trust for which Mr. Kao serves as trustee.
A selling holder has filed a notice to sell up to 596,000 shares of ALHC common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale has an aggregate value of $12,533,880.00, with ALHC common stock listed on NASDAQ. ALHC had 206,733,823 shares of common stock outstanding as of this notice, which is a baseline figure, not the amount being sold. In the past three months, the same plan sold shares on three dates with specified share amounts and proceeds.
Hochradel Shane J. reported acquisition or exercise transactions in this Form 4 filing.
Alignment Healthcare, Inc. reported that Chief Operations Officer Shane J. Hochradel received an award of 87,719 restricted stock units, each representing the right to receive one share of common stock. These RSUs vest in roughly equal installments on March 13, 2027, 2028 and 2029, conditioned on his continued service. Following this compensation-related grant, his reported holdings from this award total 87,719 units.
Alignment Healthcare, Inc. executive Joseph S. Konowiecki, EVP of Corporate Affairs and a director, sold 25,000 shares of common stock in an open-market transaction at $24.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on 03/04/2026. After this transaction, he directly holds 1,103,816 shares, so the sale represents a relatively small portion of his overall stake.
ALHC filed a Form 144 reporting proposed sales and recent dispositions of its common stock. The filing lists 75,000 shares tied to a stock bonus (vesting date 10/06/2014) and records three sales by Joseph Konowiecki of 25,000 shares each on 06/11/2026, 06/18/2026, and 06/26/2026 with gross amounts of $525,000, $550,000, and $600,000 respectively.
Alignment Healthcare, Inc. executive Joseph S. Konowiecki, EVP of Corporate Affairs and a director, reported an open-market sale of 25,000 shares of Common Stock at $23.00 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on 03/04/2026, indicating it was pre-arranged. After the sale, he directly owns 1,128,816 shares, so the transaction represents a relatively small portion of his overall holdings.
ALHC submitted Form 144 reporting insider sales of Common stock by Joseph Konowiecki. The filing lists two sale notices: 06/11/2026 for 25,000 shares and 06/18/2026 for 25,000 shares. The broker listed is Merrill Lynch at 101 S Rodeo Drive, Beverly Hills.
Alignment Healthcare executive reports planned stock sale. EVP of Corporate Affairs Joseph S. Konowiecki sold 25,000 shares of Alignment Healthcare, Inc. common stock in an open-market transaction at $22.00 per share. Following this sale, he directly holds 1,153,816 shares. A footnote states the transaction was carried out under a Rule 10b5-1 trading plan adopted on 03/04/2026, indicating the sale was pre-arranged rather than timed discretionarily.